June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Randomized comparison of anterior chamber inflammatory activityin eyes treated with intravitreal aflibercept or ranibizumab
Author Affiliations & Notes
  • Katharina Eibenberger
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Florian Sulzbacher
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Sandra Rezar
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Philipp Ken Roberts
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Stefan Sacu
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Ursula Schmidt-Erfurth
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships Katharina Eibenberger, None; Florian Sulzbacher, None; Sandra Rezar, None; Philipp Roberts, None; Stefan Sacu, Allergan (F), Askin (F), Bayer (F), Novartis (F), Pharmaselekt (F); Ursula Schmidt-Erfurth, Alcon (F), Bayer (F), Boehringer Ingelheim (F), Novartis (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1517. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Katharina Eibenberger, Florian Sulzbacher, Sandra Rezar, Philipp Ken Roberts, Stefan Sacu, Ursula Schmidt-Erfurth; Randomized comparison of anterior chamber inflammatory activityin eyes treated with intravitreal aflibercept or ranibizumab. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1517.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate anterior chamber inflammation in patients with neovascular age-related macular degeneration (AMD) after an intravitreal aflibercept (IVA) or ranibizumab (IVR) treatment.

Methods: 66 eyes of 50 patients were included in this prospective, comparative, controlled study. 50 eyes randomly received 1:1 either IVA or IVR in eyes with treatment naive neovascular AMD. 16 fellow eyes without any treatment served as a control. Anterior chamber flare was measured with the Kowa FM-500 ® laser flare meter (Kowa Company, Ltd. Tokyo, Japan) at baseline (BSL), one day, one week and one month after treatment. Measurements were expressed in counts/millisecond (counts/ms).

Results: 19 men and 31 women (mean age: 77.2±12.1 years) were included. The flare value at baseline was 9.7±6.6 counts/ms in the IVA group (n=25), 8.5±4.2 counts/ms in the IVR (n=25) and 7.4±3.0 counts/ms in the control group. No statistically significant differences were observed (IVA vs. IVR p=0.45; IVA vs. control p=0.20; IVR vs. control p=0.36). At one month, the anterior chamber flare was 9.0±4.5 counts/ms in the IVA group (BSL vs. 1month: p=0.85), 8.9±6.6 counts/ms in the IVR group (BSL vs. 1month: p=0.89) and 7.7±3.8 counts/ms in the control group (BSL vs. 1month: p=0.86).

Conclusions: Intravitreal injection of aflibercept or ranibizumab in neovascular AMD causes no statistically significant ocular inflammatory reaction.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×